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purposes, prExtracellular deoxyribonucleases (DNases) contribute to the spread of pathogenic bacteria through the evasion from
host innate immunity. Our main objective was to evaluate the production of extracellular DNases by human and bo-
vine Streptococcus agalactiae clinical strains and perform a correlation of genetic lineages and DNase activity with
capsular type, genetic determinants, clinical origin (colonization and infection), and host (human or bovine). DNase
activity was evaluated by qualitative and quantitative assays for a collection of 406 human (n = 285) and bovine (n
= 121) strains. All (121/121) bovine were isolated from mastitis and revealed to be DNase (+), indicating a putative
pathogenic role in this clinical scenario. From the human S. agalactiae strains, 86% (245/285) showed DNase ac-
tivity, among which all strains belonging to capsular types, namely, Ia, Ib, III-2, and IV. All CC17 strains (n = 58)
and 56/96 (58.3%) of the CC19 displayed DNase activity. DNase (−) strains belonged to the CC19 group. How-
ever, the subcharacterization of CC19 S. agalactiae strains through multiple-locus variable number tandem repeat
analysis (MLVA), antibiotic resistance, mobile elements, and surface proteins did not provide any distinction among
DNase producers and non-producers.
The production of DNases by all human CC17 strains, about two-fifths of human CC19, and all bovine strains,
suggest an important contribution of DNases to hypervirulence.
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agalactiaeIntroduction
Genetic lineages of Streptococcus agalactiae, such as geno-
type III ST17, have been considered highly virulent because
of their association with the development of meningitis in neo-
nates. This may be due to their intrinsic invasive characteris-
tics that would turn them more prone to invade the central
nervous system than other lineages [1–3]. However, the mo-
lecular mechanisms underlying the transition from coloniza-
tion to infection have yet to be disclosed, and while the exact
pathogenic features of S. agalactiae remain unrevealed, many
virulence factors have been proposed to explain S. agalactiae-
infection-related pathogenesis. These include the serotype-
specific polysaccharide capsule, secreted enzymes, such as hy-
aluronidase and C5a peptidase [2, 4–6], and the activity of
extracellular deoxyribonucleases (DNases) [7]. Extracellular
DNase production, described for S. pyogenes [8], S. pneumo-
niae [9], Staphylococcus aureus [10], and S. agalactiae
[7, 11], was shown to promote neutrophil-mediated resistance
and the spread of infection in vivo [12]. DNases would protect
streptococci from being killed by neutrophil extracellular traps
(NETs), by degrading this neutrophil-mediated antimicrobial
system (most associated to Gram positives). However, bacteria
might escape NET entrapment through the production of nu-
cleases. The identification of the major nuclease (nuclease A)orrespondence: National Institute of Health, Avenida Padre Cruz,
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ovided the original author and source are credited, a link to thecoding gene (gbs0661) in S. agalactiae, in 2013 [7], provided
the genetic background for the observed DNase activity first
reported in 1980 [11].
As there remains a little knowledge regarding DNase activ-
ity in human and no data concerning bovine S. agalactiae
strains, we aimed to determine DNase activity (qualitatively
and quantitatively) in strains of different origin (human and
bovine) and different capsular types to evaluate possible asso-
ciations with genetic features.
Materials and Methods
Strain Collection. S. agalactiae reference strains belonging
to different genetic lineages were used in this study: 2603V/R
(genotype: V/ST110) (ATCC BAA-611, GenBank accession
number NC004116), COH1 (genotype: III/ST17) (GenBank
accession number AAJR01000000), NEM316 (genotype:
III/ST23) (ATCC 12403, GenBank accession number
NC004368), 090R (genotype: Ia/ST25) (ATCC 12386,
GenBank accession number NZ_LCXR00000000.1), and
A909 (genotype: Ia/ST7) (ATCC BAA-1138, GenBank
accession number NC007432.1). Clinical strains of bovine
(n = 121) and human (n = 285) origin were also used.
All bovine S. agalactiae strains included in this study were
associated with clinical and sub clinical mastitis cases identi-
fied in different farms of Portugal in 2002–2003 and in 2011–
2013, n = 60 and n = 61, respectively. These strains were pre-
viously described elsewhere [13, 14].
For the human S. agalactiae collection (colonization and in-
vasive infection), a stratified sample (n = 285) from anuropean Journal of Microbiology and Immunology 8(2018)4, pp. 149–154
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DNase Production in Human and Bovine S. agalactiaeenlarged set involving the collections of the Portuguese Na-
tional Institute of Health (NIH), Portugal, and the Institute of
Medical Microbiology and Hygiene (IMMH), Ulm University,
Germany, was used. These strains have been previously de-
scribed [15–20]. The stratification of the different capsular
types to be included in the study was statistically established
by using the computer program SPSS (SPSS software, version
16.0, IBM; Fisher Exact test, significance of 5%), based on
the distribution of the capsular types (data not shown). The
desirable number of genotype II invasive strains in neonatal
infections was not achieved due to the low prevalence of this
genotype, as described by others [18].
Capsular Genotyping, Multilocus Sequence Typing
(MLST). Distribution of capsular genotypes is shown in
Table 1. Capsular genotyping for most of the bovine strains
has been previously described [13, 14]; for 13 of them (from
the 2011–2013 group), the capsular genotype could not be
identified because polymerase chain reaction (PCR)
amplification of cpsD-cpsE-cpsF did not succeed. Capsular
types designated as “New” identify strains, evidencing no
similarity with alleles included in the cpsD-E-F database [14,
17]. For the human S. agalactiae collection, all the capsular
genotypes have been identified for the purposes of prior
studies of the Portuguese NIH and the IMMH group [15–19].
MLST allelic profile or sequence type (ST) was known for
most of the strains included in prior publications [13–18].
Whenever the MLST was missing, it was determined as previ-
ously described [21], where clonal complexes (CCs) were de-
fined for isolates sharing six or seven identical alleles. For
seven bovine isolates, the ST could not be determined.
The study collection involved 3 bovine S. agalactiae genetic
lineages, CC1, CC23, and CC61, and five human S. agalactiae
genetic lineages, CC1, CC12, CC17, CC19, and CC23.
DNase Activity – Qualitative Assays. Qualitative
evaluation of DNase production was performed for all S.
agalactiae strains; this was done by inoculation of DNA–
methyl green agar plates (Oxoid, Basingstoke, England) or
DNase test agar with toluidine blue plates (Sigma-Aldrich,
USA). S. agalactiae strains, namely, 090R, COH1, or
NEM316, were used as positive controls, and 2603V/R as a
negative control. The interpretation of the results was done
after 24 h of incubation at 37 °C in an atmosphere of
5% CO2. Strains were considered DNase producers when
displaying transparent halos around colonies of S. agalactiae
in DNA–methyl green agar plates, or a characteristic bright
rose-pink zone in DNase test agar with toluidine blue.Table 1. Collection of S. agalactiae strains used in the present study
Capsular
serotype/genotype
Number of human colonizing
strains (n = 157)a
Number of h
strains
Ia 20
Ib 10
II 39
III-I 29
III-2 29
III-3
IV 10
V 20
New cpsBOV
e 1
New cpsBOV 2
New cpsBOV 3
New cpsBOV 4
New cpsBOV 5
New cpsBOV 6
New cpsBOV 7 to new cpsBOV 15
aThese strains were previously described [15–17].
bThese strains were previously described [18–20].
cBovine strains from 2002–2003 have been previously described [13, 14].
dFor 13 bovine strains from 2011–2013, the capsular genotype could not be de
eNew cpsBOV: new bovine capsular type.
150DNase Activity – Semi-Quantitative and Quantitative
Assays. The semi-quantitative assessment of the activity of
DNases was performed according to that described by Sumby
et al. [8], with modifications, in order to confirm the results
of the qualitative testing. Briefly, S. agalactiae strains were
inoculated in 5 mL of Todd Hewitt broth supplemented with 0.5%
yeast extract (Oxoid), culture supernatant from stationary phase
was centrifuged (10 min, 3000 rpm), syringe-filtrated (0.2 μm),
before incubation at 37 °C with 1 μg of double-stranded DNA
(dsDNA) (atr amplicon [21]) in the presence of 1× M buffer
(Roche). Filtrated supernatants (10 μL) were incubated for 1 h, 2
h, 4 h and “overnight” (∼ 17 h) in order to evaluate the digestion
of DNA in a final volume of 50 μL. Nuclease reaction was
stopped by adding ethylenediaminetetraacetic acid EDTA (0.5 M,
pH 8.0) at 4 °C. DNA digestion was analyzed by electrophoresis
in 1% agarose gel. S. agalactiae strains 090R, COH1, or NEM316
were used as positive controls. A negative control consisting on a
reaction mixture without supernatant was used in all experiments.
Qualitative and semi-quantitative assays yielded identical re-
sults. An example of semi-quantitive testing is shown in Fig-
ure 1. The quantitative evaluation of the activity of DNases
was only performed for a selection of S. agalactiae strains, in-
cluding null or residual producers in qualitative and semi-
quantitative assays. The quantitative DNase assays were per-
formed as described above, and the amount of DNA present in
each sample was determined by measuring at the same time
points of incubation. For this purpose, the fluorescent Pico-
Green dye (Invitrogen) was used to quantify the dsDNA
according to the manufacturer's instructions (https://www.ther-
mofisher.com/order/catalog/product/P7589). Briefly, 1 mL of
1× Quant-iT PicoGreen was added to an equal volume of each
supernatant, previously diluted in 1× Tris–EDTA (TE) buffer.
After 5 min of incubation at room temperature, in the dark, we
proceeded to the fluorescence measurement (Fluorimeter –
Anthos Zenith 3100) in 96-well microtiter plates (Corning 96
Well Clear Flat Bottom Polystyrene Black TC, Costar, USA).
To calculate the concentration of remnant DNA in each sam-
ple, a standard curve with 4 solutions of phage Lambda DNA
of known concentrations (1, 10, 100, and 1000 ng/mL) was
used: y = 3675x (x = concentration of dsDNA ng/mL, y = fluo-
rescence) (see supporting information Figure 1). Each obtained
fluorescence value was subtracted to the blank solution (Pico-
Green 1× + 1× TE buffer at a ratio of 1:1) fluorescence value.
S. agalactiae strains, namely 090R, COH1, and NEM316 were
used as positive controls, and 2603V/R as a negative control.
The results were based on 2 independent experiments.uman invasive
(n = 128)b
Number of bovine strains
from 2002–2003 (n = 60)c
Number of bovine strains
from 2011–2013 (n = 61)d
20
10
17
29
29
1
3
20 14
6 1
11
24 28
1
3
10
1 isolate of each type
termined. Part of these strains were previously described [13].
Figure 1. Semi-quantitative assay in gel electrophoresis for the evaluation of DNase activity. 1 μg of DNA (amplicon atr) incubated with 10 μl
of S. agalactiae culture supernatant (NEM316 vs CC19 clinical strain) for 1h, 2h, 4h, overnight at 37°C. Neg, Negative control: without culture
supernatant; ON, Overnight; M, Molecular weight Ladder.
C. Florindo et al.Multiple-Locus Variable Number Tandem Repeat
Analysis (MLVA). For determining the MLVA genotype, the
variable number of tandem repeats present in SAG2, SAG3,
SAG4, SAG7, SAG21, and SAG22 genes according to
nucleotide sequences of the reference strains, namely,
2603V/R, NEM316, and A909, was evaluated; this was done
as described elsewhere [22].
S. agalactiae Antimicrobial Resistance Profile.
Antimicrobial resistance testing (penicillin G, erythromycin,
clindamycin, and vancomycin) was performed by Epsilometer
test (E-test) according to Clinical and Laboratory Standards
Institute guidelines [23] and by the detection of macrolide-
resistance-associated genes (ermTR, ermB, and mefA) through
PCR amplification, as described elsewhere [24].
Alpha-like Protein (Alp) Family and Mobile Genetic
Elements. The major surface-localized protein antigens of S.
agalactiae belong to a family of surface proteins named
Alp family, which contains large internal tandem repeats
and is a potential virulence factor. A multiplex PCR was
used for direct identification of the Alp family (alpha-C,
rib, epsilon, and alp2–alp4 genes) [25, 26].
Genes encoding the surface proteins ScpB and Lmb are lo-
cated on a composite transposon that appears to be a hot spot
for integration of two MGEs, GBSi1, or IS1548. Several
MGEs are genetic markers for particular genetic lineages. In-
deed, CC17 is usually marked by the group II intron GBSi1,
whereas CC19 is marked by the insertion sequence IS1548.
The presence of two mobile genetic elements, namely,
IS1548 and GBSi1, within the scpB–lmb intergenic region
was evaluated by PCR, as previously described [27]. In the
absence of mobile genetic elements, the presence of the flank-
ing genes (scpB and lmb) was assessed.
Statistical Analysis. Associations between categorical
variables (DNase producers/non-producers and colonization/
invasive infection) were calculated using Chi-square with a
significance level of 5%. All presented statistical results were
obtained using SPSS, version 16.0 (SPSS Inc.).
Ethics
No ethical approval was obtained because our work in-
volves only in vitro assays involving prototype strains andanonymized strains from laboratory collections. No relation to
specific individuals is performed. No personal data are in-
volved in the present study.
Results
DNase Assays. All bovine S. agalactiae strains (121/121)
and 86% (245/285) of the human S. agalactiae strains
displayed DNase activity.
All human strains belonging to capsular types Ia, Ib, III-2,
and IV displayed DNase activity; the percentage of DNase
producing strains among types II, III-1, and V varied between
82% and 88%, 48% and 59%, and 90%, respectively, depend-
ing on the clinical origin (colonization or invasive infection),
and sequence type/clonal complex (Tables 2 and 3).
All DNase (−) strains (40/406; 9.9%; all from human origin)
belonged to CC19; however, 56 CC19 strains (involving cap-
sular types II/III-1) within the present study collection dis-
played DNase activity (Table 2). The quantitative DNase
activity over time within the population of CC19 strains is
shown in Figure 2. In accordance with these results, prototype
strain 2603V/R showed a disability to degrade DNA, whose
amount remained nearly constant after 17 h. In contrast, S.
agalactiae NEM316, COH1, 090R, and various clinical
strains, belonging to CC17, CC23, and CC61 genetic lineages,
revealed a substantial digestion of the DNA, reflecting a high
production of extracellular DNases (Figure 2). Except ST61
strains (all of bovine origin), the profiles of DNA digestion
were quite similar within strains of the same ST (Figure 2).
No statistical association between DNase production and in-
vasive infection could be established (P > 0.05) for human S.
agalactiae isolates. For bovine, strains from colonization or
systemic infections were not available, precluding any statisti-
cal evaluation of clinical findings for DNase production.
Sub-Characterization of CC19 Strains. For further
phenotypic characterization and to identify putative genetic
determinants associated with the production/non production of
DNases, CC19 was selected (all strains isolated from humans)
(n = 96, 55 colonizing strains, and 41 invasive strains). Based
on MLVA, two profiles/genotypes were identified: profile 33
(3,3,3,5,0,2) exhibited by all ST19 strains, and profile 32
(3,3,1,5,0,2) exhibited by ST28 strains.151
Table 2. Evaluation of the DNase activity by qualitative and semi-quantitative assays among S. agalactiae of human origin (ST = sequence type; CC =
clonal complex)
Strains with DNase activity (frequency)
[STs (frequency)]
CCs (frequency)
Capsular
type
Colonization Invasive infection
Ia
100% (20/20) 100% (20/20)
[ST23 (17/20); ST144 (2/20); ST24 (1/20)] [ST23 (19/20); ST24 (1/20)]
CC23 (20/20) CC23 (20/20)
Ib
100% (10/10) 100% (10/10)
[ST8 (5/10); ST12 (2/10); ST1 (1/10); ST10 (1/10); ST563 (1/10)] [ST10 (5/10); ST8 (4/10); ST12 (1/10)]
CC1 (2/10); CC12 (8/10) CC12 (10/10)
II
82% (32/39) 88% (15/17)
[ST 28 (10/32); ST12 (8/32); ST44 (4/32); ST10 (3/32); ST2 (2/32); ST43 (1/32);
ST154 (1/32); ST249 (1/32); ST347 (1/32); ST 472 (1/32)]
[ST 12 (5/15); ST28 (4/15); ST19 (3/15); ST10
(1/15); ST22a (1/15); ST42 (1/15)]
CC19 (17/32); CC12 (12/32); CC1 (2/32); CC23 (1/32) CC19 (8/15); CC12 (6/15)
III-1
48% (14/29) 59% (17/29)
[ST19 (8/14); ST27 (2/14); ST106 (2/14); ST286 (1/14); ST369 (1/14)] [ST19 (17/29)]
CC19 (14/14) CC19 (17/17)
III-2
100% (29/29) 100% (29/29)
[ST17 (28/29); ST287 (1/29)] [ST17 (29/29)]
CC17 (29/29) CC17 (29/29)
IV
100% (10/10) 100% (3/3)
[ST196 (3/10); ST1 (1/10); ST2 (2/10); ST3 (1/10); ST162 (1/10); ST23 (1/10);
ST10 (1/10)]
[ST66 (1/3); ST8 (1/10); ST23 (1/10)]
CC1 (7/10); CC23 (2/10); CC12 (1/10) CC1 (1/3); CC23 (1/3); CC12 (1/3)
V
90% (18/20) 90% (18/20)
[ST1 (5/18); ST2 (13/18)] [ST1 (15/18); ST2 (1/18); ST23 2/18)]
CC1 (18/18) CC1 (16/18); CC23 (2/18)
aSingleton ST.
DNase Production in Human and Bovine S. agalactiaeRegarding the antibiotic resistance testing, no CC19 strain
was resistant to penicillin (minimum inhibitory concentrationTable 3. Evaluation of the DNase activity by qualitative and semi-quantitative as
St
Capsular type Collection of 2002–2003
III-3
100% (1/1)
[ST23 (1/1)] CC23 (1/1)
V
100% (14/14)
[ST2 (14/14)] CC1 (14/14)
New cpsBOV 1
100% (6/6)
[ST2 (6/6)] CC1 (6/6)
New cpsBOV 2
100% (11/11)
[ST61 (11/11)] CC61 (11/11)
New cpsBOV 3
100% (24/24)
[ST61 (4/24); ST554 (20/24)]
CC61 (24/24)
New cpsBOV 4
100% (1/1)
[ST61 (1/1)] CC61 (1/1)
New cpsBOV 5
100% (3/3)
[ST2 (3/3)] CC1 (3/3)
New cpsBOV 6
New cpsBOV 7
New cpsBOV 8
New cpsBOV 9
New cpsBOV 10
New cpsBOV 11
New cpsBOV 12
New cpsBOV 13
New cpsBOV 14
New cpsBOV 15
ST = Sequence type; CC = Clonal Complex; New cpsBOV = new bovine capsu
152[MIC] between 0.032 and 0.125 μg/mL) and vancomycin
(MIC between 0.25 and 1 μg/mL). In addition, no invasivesays among S. agalactiae of bovine origin
rains with DNase activity (frequency);
[STs (frequency)] CCs (frequency)
Collection of 2011–2013
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (28/28)
[ST61 (3/28); ST554 (23/28); ST2 (1/28);
ST N.D. (1/28)] CC1 (1/28)] CC61 (26/28)
100% (10/10)
[ST61 (7/10); ST554 (2/10); ST N.D. (1/10)] CC61 (9/10)
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (1/1)
[ST554 (1/1)] CC61 (1/1)
100% (1/1)
[ST61 (1/1)] CC61 (1/1)
100% (1/1)
[ST N.D. (1/1)]
lar type; N.D. = not determined.
Figure 2. Quantitative DNase assays displaying differential DNase activity between S. agalactiae strains over time. 1 μg of DNA (amplicon atr)
incubated with 10 μl of S. agalactiae culture supernatant for 1h, 2h, 4h, overnight at 37°C. Fluorescent PicoGreen dye (Invitrogen) was used to
quantify the dsDNA. The graphic displays the mean values of the experiment performed in duplicate. Error bars show ± standard deviation (see
Supporting information Table 1). Col, Colonization; Inf, Infection; Bov, Bovine; C.S., Clinical Strain; R.S., Reference Strain; PC, Positive Control;
NC, Negative Control
C. Florindo et al.CC19 strain displayed resistance to macrolides, contrasting to
colonizing CC19 strains, which have shown a macrolide resis-
tance rate of 31% (17/55; III-1, 16 strains; II, one strain). Nine
of these 17 strains showed simultaneous resistance to erythro-
mycin and clindamycin, MIC ≥ 256 mg/mL, attributable to
the presence of ermB gene. The remaining CC19 strains were
only resistant to erythromycin, 2 ≤ MICs ≤ 6 μg/mL, present-
ing ermA (n = 8) and mefA (n = 1). There was no statistical
correlation between antibiotic resistance profile and DNase ac-
tivity among CC19 strains.
The screening of mobile genetic elements within the scpB-
lmb intergenic region and the study of Alp genes also failed to
distinguish among human CC19 DNase producers and non-
producers. In fact, 79.2% (76/96) of the CC19 strains carried
the IS1548, whereas 100% (96/96) displayed the rib gene.
Discussion
Our study aimed to evaluate DNase production among a
human strain collection statistically stratified to represent the
different S. agalactiae capsular types (except genotype II be-
cause of the lack of invasive strains of this capsular type in
the collection available for the study) and to correlate DNase
production with clinical and genotypic features.
In bovine S. agalactiae, to our best knowledge, this is the
first study reporting DNase activity, and a high DNase activity
was determined, in particular, among strains belonging to the
ST61 lineage. Considering that neither colonization strains,nor bovine DNase non-producer strains were available, no fur-
ther association could be established.
Qualitative and semi-quantitative assays are easy to execute
and have been proposed to determine DNase activity [8].
However, they are inaccurate to fully characterize the produc-
tion of DNases, and for this reason, a quantitative methodol-
ogy was applied in the present study. Using this approach,
100% and 86% of the bovine and human strains, respectively,
displayed DNase activity. For human strains, these results
corroborate the earlier findings [11] describing exactly the
same 86% of DNase producers among strains from human
origin.
ST17 strains belonging to the capsular type III have long
been associated with meningitis and late onset disease of the
newborn. These strains display secreted and surface-exposed
factors, among which DNases that have been related to viru-
lence [2, 4]; accordingly, in our study, all ST17 strains were
DNase producers. Thus, although less often related to menin-
gitis (in contrast to ST17 strains), CC19 strains attracted our
attention, as this less studied group involves both DNase (+)
and DNase (−) strains, a phenotype that was only found
among the CC19 genetic lineage. These strains belonged to
capsular types II, III-1, and V, contrasting with CC17 strains,
which were all capsular type III-2 and DNase producers. The
production of DNases by all CC17 strains, in contrast to the
absence of DNase production in 41.7% (40/96) of the CC19
strains, could suggest a contribution of DNases to hyperviru-
lence. However, in the present study, CC19 strains were153
DNase Production in Human and Bovine S. agalactiaeinvolved in both colonization and invasive infection; thus,
CC19 strains also could not be associated with colonization,
not corroborating the hypothesis proposed by others [3].
In our attempt to deeper characterize the subpopulation of
CC19 producer and non-producer strains, we used MLVA, as
some authors defined MLVA as an epidemiological tool dis-
playing higher discriminatory power than MLST [22]. How-
ever, the polymorphism of tandem repeats obtained by this
technique only reinforced the clonality of CC19 strains previ-
ously obtained by MLST. Thus, MLVA did not provide the
separation of CC19 strains in clones associated with the pro-
duction/non production of extracellular DNases. Also, the
study of Alp genes and the search for mobile genetic elements
in the intergenic region scpB-lmb (located on a composite
transposon and a hot spot for integration of IS1548 or group
II intron GBSi1) did not provide new evidence for distinguish-
ing CC19 subpopulations according to their DNase activity. In
addition, DNase coding genes and antibiotic resistance genes
do not seem to be genetically related, as no association be-
tween antibiotic resistance and DNase production could be
established.
All bovine strains (all DNase (+)) were isolated from masti-
tis, highlighting the need for extensive studies in cattle. In
fact, udder infections by S. agalactiae DNase (+) strains might
induce serious economic repercussions over milk production,
as DNase production might be advantageous to overcome bo-
vine host mammary tissue NETs and thus facilitating infection
establishment; if this hypothesis is confirmed in future studies,
DNases could be useful for the development of a vaccine for
preventing S. agalactiae mastitis.
In conclusion, this study contributes for the perception of
DNase production among S. agalactiae from human and, for
the first time, bovine origin, characterizing 406 strains regard-
ing the capsular type, sequence type, and antimicrobial resis-
tance factors. The high percentage of strains evidencing
DNase activity (100% of bovine origin and 86% of human or-
igin), including all CC17 human strains, seems to corroborate
the hypothesis of a major role of this enzyme in the evasion
processes from the host defense mechanisms, namely NETs,
and a putative role in hypervirulence. The circumstance that
all bovine strains were DNase (+) and all were isolated from
mastitis highlights the need for an extensive evaluation of S.
agalactiae infections in bovine, to fully understand whether
DNase production is required for the development of mastitis.
Comparative whole-genome sequencing studies together with
a large-scale transcriptomic analysis involving strains of di-
verse origin should be crucial to deeply scalp the molecular
features associated to DNase release and activity.Funding Sources
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Supporting information Table 1 Standard deviations obtained in quantitative DNase 
assays 
Strains Time (hours) Standard deviation (%) 
1351/07 
1 0,09 
2 3,9 
4 0,85 
17 1,4 
92/05 
1 1,69 
2 0,76 
4 0,56 
17 0,78 
44 
1 0,86 
2 2,77 
4 0,94 
17 0,76 
80 
1 0,38 
2 1,89 
4 1,03 
17 0,8 
204/08 
1 1,82 
2 0,35 
4 0,58 
17 1,1 
423/08 
1 0,38 
2 1,89 
4 1,03 
17 0,92 
320 
1 1,61 
2 0,23 
4 1,71 
17 0,55 
280 
1 2,57 
2 1,23 
4 0,9 
17 1,3 
1288/07 
1 5,57 
2 2,16 
4 1,12 
17 0,9 
32 
1 3,1 
2 1,43 
4 0,36 
17 1,01 
 
Strains Time (hours) Standard deviation (%) 
708/08 
1 1,6 
2 2,1 
4 1,95 
17 3,3 
69 
1 2,7 
2 1,89 
4 1,3 
17 1,46 
1178/07 
1 0,72 
2 0,9 
4 0,65 
17 1,1 
360 
1 1,47 
2 0,89 
4 0,26 
17 0,67 
VSA16 
1 0,8 
2 1,2 
4 0,71 
17 0,3 
VSA29 
1 1,2 
2 0,85 
4 0,63 
17 1,32 
NEM316 
1 1,6 
2 1,2 
4 1,08 
17 0,95 
COH1 
1 1,11 
2 0,98 
4 0,74 
17 0,95 
090R 
1 0,35 
2 0,68 
4 1,25 
17 0,8 
2603V/R 
1 1,23 
2 0,64 
4 1,09 
17 0,55 
 
 
 
 
 
Supporting information Figure 1 Standard curve for quantitative DNase assays  
A standard curve with four solutions of phage Lambda DNA of known concentrations 
(1, 10, 100 and 1000 ng/ml) was used: y = 3675x (x = concentration of dsDNA ng/ml, y 
= fluorescence). 
 
 
